Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Unexpected Synergy Reveals New Therapeutic Strategy in SCLC.

Literature DB >> 30975441

Unexpected Synergy Reveals New Therapeutic Strategy in SCLC.

Abstract

DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.

Entities: Disease

Keywords: PARP inhibitor; PD-1; PD-L1; SCLC; checkpoint kinase 1 inhibitor; immune checkpoint blockade

Mesh：

Year: 2019 PMID： 30975441 DOI： 10.1016/j.tips.2019.03.005

Source DB: PubMed Journal: Trends Pharmacol Sci ISSN： 0165-6147 Impact factor: 14.819

Keyword Cloud
Cited

4 in total

Unexpected Synergy Reveals New Therapeutic Strategy in SCLC.

1. Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients.

Review 2. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.

Review 3. Prospects for combining immune checkpoint blockade with PARP inhibition.

Review 4. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].